What a NextGenAMR result is designed to contain: a quality-control verdict with reason codes, species confirmation, the resistance mechanisms detected, a probability of resistance with its uncertainty for each antibiotic in the predictive panel — or an abstention with its reason — and the provenance of every step. No results are shown on this website.
We are building evidence-grade genomic intelligence for antimicrobial resistance.
NextGenAMRIn development Not for clinical use
Vanguard Biotech Systems is a Spanish biotechnology software company. Our first product, NextGenAMR, is being designed to estimate antibiotic resistance from the genome of a cultured bacterial isolate.
NextGenAMR
In development. The E. coli engine is being built and will be evaluated internally under a pre-specified protocol. An independent external validation protocol has been drafted. No performance results have been published. Not for clinical use.
AMR, quantified.
AMR is not an abstract problem. It is measurable.
1.27M
Estimated global deaths directly attributable to bacterial antimicrobial resistance in 2019.
4.95M
Estimated global deaths associated with bacterial antimicrobial resistance in 2019.
Source: Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. The Lancet 2022;399:629–55.
Not another AMR tool. A controlled intelligence layer.
Genomic AMR interpretation today is often spread across disconnected scripts, databases, spreadsheets and manual judgement. Workflows composed of multiple tools can make it difficult to maintain consistent versions, provenance, handoffs and reporting across teams and runs. NextGenAMR is designed to bring that work into one auditable layer.
From genome to evidence · concept, no data
01
Cultured isolate
A single bacterial isolate, grown in the laboratory.
02
Whole-genome sequence
Paired-end sequencing reads of that isolate.
03
Resistance mechanisms
Three mechanism classes, encoded separately.
04
Evidence record
Per-antibiotic estimates with uncertainty or abstention — designed, not yet released.
Integrated
Designed as one workflow instead of a fragmented toolchain spread across teams and runs.
Auditable
Designed so that every result carries its evidence, versions and provenance.
Reproducible
Designed so that every step runs in pinned, versioned software and can be repeated.
NextGenAMR scope today
NextGenAMR is designed to be species-aware: each species has its own panel, features and models. The first species is Escherichia coli.
- First species
- Escherichia coli — In development
- Candidate first panel
- Ampicillin, Ciprofloxacin, Cefotaxime, Ceftazidime, Gentamicin — Subject to evaluation
- Carbapenems
- Carbapenems: genotypic evidence only, with no model probability.
- Next species
- Klebsiella pneumoniae — Planned
Where NextGenAMR stands · October 2026
Built (internal R&D)
Per-batch provenance — A write-once record of what produced each processing batch
Quality and species checks — Unsupported inputs rejected or flagged, with reason codes
In development
NextGenAMR engine
Escherichia coli
Designed
Pinned, versioned software — Every step designed to run in pinned, versioned software and be repeatable
Uncertainty and abstention — At model level: designed, not yet validated
Planned
Next planned species: Klebsiella pneumoniae.
Not claimed
Clinical use — Not for clinical use · outputs for professional review · not autonomous
NextGenAMR is in development and is not intended for clinical use. It has no authorisation or declaration of conformity for clinical diagnostic use: no CE marking under the EU In Vitro Diagnostic Regulation (IVDR, Regulation (EU) 2017/746) and no FDA marketing authorisation. No ISO 13485 quality-management certification is claimed.
Help establish independent evidence for genomic AMR interpretation.
NextGenAMR is in development. We welcome conversations with clinical, research and surveillance institutions about future validation collaborations.
Vanguard Biotech Systems.
Vanguard Biotech Systems is a Spanish biotechnology software company developing genomic intelligence systems for antimicrobial resistance. It was incorporated as a Sociedad de Responsabilidad Limitada (S.L.) in 2025, with its operational base in Granada and its registered office in Lepe, Huelva.
- Location
- Granada, Spain
- Focus
- AMR · WGS · Bioinformatics
Acknowledgements
This project would not exist without the people behind it. To the team — Ángel, Alejandro, Juan Carlos and Irene — for the work, the care and the long hours. To José Luis, for believing in it when it was only an idea. To my family, and above all to my parents, for everything. And to everyone who, directly or indirectly, made NextGenAMR possible — thank you, always.